AVXL241220C5000
- 2.89
- 0.000.00%
Anavex Life Sciences Newsroom
Calendar of U.S. Earnings Expected in the Week Ahead
Earnings Week Ahead: NVDA, WMT, SNOW, TGT, BIDU, NIO, ZIM, and More
Anavex Life Sciences Corp. (NASDAQ:AVXL): Is Breakeven Near?
Express News | HC Wainwright & Co. Reiterates Buy on Anavex Life Sciences, Maintains $40 Price Target
Anavex Life Sciences: Buy Rating Driven by Promising Blarcamesine Developments and Market Expansion
Anavex Life Sciences Shares Are Trading Higher After the Company Announced New Data From the Phase IIb/III Study Showing That Blarcamesine, Once Daily Orally, Demonstrates Pre-specified Clinical Efficacy Through Upstream SIGMAR1 Activation.
12 Health Care Stocks Moving In Thursday's Intraday Session
JonesTrading Maintains Anavex Life Sciences(AVXL.US) With Buy Rating, Maintains Target Price $15
Anavex Life Sciences Is Maintained at Buy by EF Hutton
Anavex Gains as Lead Asset Slows Alzheimer's Disease Progression by a Third
Anavex Reports Phase III Results for Alzheimer's Drug Targeting SIGMAR1 Gene
Express News | Anavex Life Sciences Corp - Regulatory Submission of Blarcamesine in Europe Expected This Quarter
Express News | Anavex Life Sciences Corp - Blarcamesine Slows Clinical Progression by 36.3% Over 48 Weeks
Anavex's Blarcamesine Achieves Pre-specified Efficacy in Phase IIb/III Alzheimer's Trial: Data Presented at CTAD Conference 2024
Express News | Anavex’s Blarcamesine Achieves Pre-Specified Efficacy in Phase Iib/III Alzheimer’s Trial: Data Presented at Ctad Conference 2024
Anavex Life Sciences Analyst Ratings
H.C. Wainwright Maintains Anavex Life Sciences(AVXL.US) With Buy Rating, Maintains Target Price $40
Buy Rating Affirmed for Anavex Life Sciences Amid Promising Clinical Developments and Market Prospects
Express News | Anavex Life Sciences Corp - Data From Part B Expected in First Half of 2025
Express News | Anavex Life Sciences Corp - Anavex(®)3-71 Well Tolerated, No Serious Adverse Events